4-<5-methyl>phenol | 132646-46-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 4-<5-methyl>phenol
• 英文别名: 3-triphenylmethyl-5-([4-hydroxyphenyl]methyl)oxazolidine-2,4-dione；3-triphenylmethyl-5-(p-hydroxybenzyl)-2,4-oxazolidinedione；5-(4-hydroxybenzyl)-3-trityloxazolidine-2,4-dione；4-[(2,4-dioxo-3-trityl-5-oxazolidinyl)methyl]phenol；5-[(4-hydroxyphenyl)methyl]-3-trityl-1,3-oxazolidine-2,4-dione
• CAS: 132646-46-9
• 化学式: C₂₉H₂₃NO₄
• 分子量: 449.506
• InChiKey: VRJXQMRLBMRYQX-UHFFFAOYSA-N

物化性质

• 熔点：
  158-161 °C
• 沸点：
  624.7±65.0 °C(Predicted)
• 密度：
  1.299±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  34
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-<5-methyl>phenol 在 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 26.5h， 生成 5-(4-{2-[2-(3,5-Bis-trifluoromethyl-phenyl)-5-methyl-oxazol-4-yl]-ethoxy}-benzyl)-oxazolidine-2,4-dione
  参考文献：
  名称：

  Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

  摘要：

  A series of benzyloxazolidine-2,4-diones, containing oxazole-based side chains, were found to lower blood glucose levels in the genetically obese ob/ob mouse. Incorporation of a benzofuran structural element in these compounds provides greatly enhanced in vivo potency. The syntheses and structure-activity relationships for this series are detailed.

  DOI：

  10.1021/jm00109a003
• 作为产物：
  描述：

  4-(氯甲基)苯基乙酸酯 、 3-Triphenylmethyl-1,3-oxazolidine-2,4-dione 在 methyl magnesium carbonate 作用下， 生成 4-<5-methyl>phenol
  参考文献：
  名称：

  Benzyloxazolidine-2,4-diones as potent hypoglycemic agents

  摘要：

  A series of benzyloxazolidine-2,4-diones, containing oxazole-based side chains, were found to lower blood glucose levels in the genetically obese ob/ob mouse. Incorporation of a benzofuran structural element in these compounds provides greatly enhanced in vivo potency. The syntheses and structure-activity relationships for this series are detailed.

  DOI：

  10.1021/jm00109a003

文献信息

• Oxazolidinedione hypoglycemic agents
  申请人：Pfizer Inc.

  公开号：US05498621A1

  公开（公告）日：1996-03-12

  Compounds of the formulae ##STR1## where R is cycloalkyl or aryl; R.sub.1 is alkyl, X is O or C.dbd.O; A is O or S; and B is N or CH are useful as hypoglycemic agents.

  式##STR1##中R为环烷基或芳基；R.sub.1为烷基，X为O或C.dbd.O；A为O或S；B为N或CH的化合物可用作降糖药。
• Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
  申请人：AstraZeneca AB

  公开号：US06288096B1

  公开（公告）日：2001-09-11

  Novel thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives, process for their manufacture, pharmaceutical preparations containing them and the use of the compounds in conditions associated with insulin resistance.

  新型噻唑烷二酮、噁唑烷二酮和噁二唑烷二酮衍生物，其制造方法，含有它们的药物制剂以及在与胰岛素抵抗相关的病症中使用这些化合物。
• Oxime derivatives, their preparation and their therapeutic use
  申请人：Sankyo Company, Limited

  公开号：US05703096A1

  公开（公告）日：1997-12-30

  Compounds of formula (I): ##STR1## wherein: R.sup.1 is hydrogen or alkyl; R.sup.2 is alkylene; R.sup.3 is hydrogen, alkyl, alkoxy, alkylthio, halogen, nitro group, amino group, monoalkylamino, dialkylamino, aryl, or aralkyl; X is aryl, or aromatic heterocyclic; Y is oxygen, sulfur or a group of formula >N-R.sup.4, in which R.sup.4 is hydrogen, alkyl or acyl; and Z is a group of formula (Za), (Zb), (Zc) or (Zd): ##STR2## and salts thereof can be used to treat or prevent are included those arising from hyperlipidemia, hyperglycemia, obesity, impaired glucose tolerance (IGT), insulin resistant non-IGT (NGT), non-diagnostic glucose tolerance, insulin resistance, diabetic complications, fatty liver, polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM); in addition the compounds of the present invention have aldose reductase inhibitory activity.

  公式（I）的化合物：其中：R.sup.1为氢或烷基；R.sup.2为烷基；R.sup.3为氢、烷基、烷氧基、烷硫基、卤素、硝基、氨基、单烷基氨基、二烷基氨基、芳基或芳基烷基；X为芳基或芳香杂环；Y为氧、硫或具有公式>N-R.sup.4的基团，其中R.sup.4为氢、烷基或酰基；Z为具有公式（Za）、（Zb）、（Zc）或（Zd）的基团：其盐可用于治疗或预防由高脂血症、高血糖、肥胖、糖耐量受损（IGT）、胰岛素抵抗非IGT（NGT）、非诊断性葡萄糖耐量、胰岛素抵抗、糖尿病并发症、脂肪肝、多囊卵巢综合征（PCOS）和妊娠糖尿病（GDM）引起的疾病；此外，本发明的化合物具有醛糖还原酶抑制活性。
• NOVEL BISHETEROCYCLIC DERIVATIVE OR SALT THEREOF
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0597102A1

  公开（公告）日：1994-05-18

  A bisheterocyclic compound represented by general formula (I), stereoisomers thereof, tautomers thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a pharmaceutical composition containing the same, and a process for the production thereof. In formula (I), R¹ and R² may be the same or different from each other and each represents (II) or (III), R3 represents hydrogen or a protective group, X, Y¹ and Y² may be the same or different from one another and each represents oxygen or sulfur, B¹ and B² represent each phenylene, B³ represents phenylene, naphthylene, cyclohexylene or furo[3,2-b]furanylene, L¹ and L² represent each -(O)n-A-, n represents 0 or 1, and A represents a single bond or lower alkylene, provided that when n is 1, A represents alkylene and the oxygen atom of each of L¹ and L² is bonded to B³. The above compounds are useful as a hypoglycemic drug based on the activity of enhancing insulin sensitivity.

  一种由通式(I)表示的双杂环化合物、其立体异构体、其同系物、其药学上可接受的盐或药学上可接受的溶液、含有其的药物组合物以及其生产工艺。在式(Ⅰ)中，R¹和R²可以相同或互不相同，各自代表(Ⅱ)或(Ⅲ)，R3代表氢或保护基团，X、Y¹和Y²可以相同或互不相同，各自代表氧或硫，B¹和B²各自代表亚苯基、L¹ 和 L² 分别代表-(O)n-A-，n 代表 0 或 1，A 代表单键或低级亚烷基，但当 n 为 1 时，A 代表亚烷基，且 L¹ 和 L² 的氧原子分别与 B³ 键合。基于提高胰岛素敏感性的活性，上述化合物可用作降血糖药物。
• DOW, ROBERT L.;BECHLE, BRUCE M.;CHOU, THOMAS T.;CLARK, DAVID A.;HULIN, BE+, J. MED. CHEM., 34,(1991) N, C. 1538-1544
  作者：DOW, ROBERT L.、BECHLE, BRUCE M.、CHOU, THOMAS T.、CLARK, DAVID A.、HULIN, BE+

  DOI：——

  日期：——